Clinical Trials Logo

Clinical Trial Summary

The main aim of the study is to investigate the effects of ±3,4-methylenedioxymethamphetamine (MDMA; ecstasy) on social and emotional processing in healthy humans. Ecstasy is a widely used recreational drug, with over 2 million Americans reporting use of the drug in 2006. With this number of users, and evidence that high doses of MDMA are neurotoxic in laboratory animals, the public health implications of ecstasy use may be substantial. Certain subjective effects of this drug distinguish it from other stimulants, and may contribute to its widespread use: That is, users report that ecstasy produces profound feelings of empathy and closeness to others. These so-called 'empathogenic' effects, which may reflect the distinctive neurochemical profile of action of the drug, have yet to be characterized in controlled laboratory studies. The investigators propose to characterize the effects of MDMA on measures of social and emotional processing that may contribute to this 'empathogenic' profile, including measures of emotion recognition, emotional responsiveness and sociability. The investigators will assess effects of MDMA (0, 0.75 and 1.5 mg/kg up to 125 mg) one active control drug (oxytocin: 20 IU) in 100 volunteers who report some prior ecstasy use. Oxytocin will be used because it appears to produce pro-social behavioral effects resembling those attributed to MDMA.


Clinical Trial Description

n/a


Study Design

Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT01849419
Study type Interventional
Source University of Chicago
Contact
Status Completed
Phase N/A
Start date July 2010
Completion date March 2013

See also
  Status Clinical Trial Phase
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT02192931 - A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users Phase 4
Completed NCT02437123 - The Cedar Project: Impact of mHealth for HIV Prevention Among Young Indigenous People Who Use Illicit Drugs N/A
Completed NCT01685073 - The Role of Sleep in the Treatment of Cannabis Use Disorders Phase 2/Phase 3
Completed NCT01591239 - Home-Based Program to Help Parents of Drug Abusing Adolescents N/A
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Completed NCT03678051 - CBT4CBT for Women in Residential Treatment for Substance Use Disorders N/A
Completed NCT04105621 - Westlake Personalized Nutrition and Health Cohort for Drug Addicts
Withdrawn NCT05440721 - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification N/A
Completed NCT03694327 - Innovative Digital Therapeutic for Smoking Cessation N/A
Completed NCT00496990 - Treating the Partners of Drug Using Pregnant Women: Stage II Phase 2/Phase 3
Completed NCT00390559 - Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3 N/A
Completed NCT00244699 - Integrating Mindfulness-Based Skills Training Into Brief Outpatient Treatment for Substance Abusing Youth N/A
Completed NCT03411265 - RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing N/A
Completed NCT03402672 - AWAITS: A Web-based E-health Application for Active Illicit Opioid Users N/A
Completed NCT01003496 - Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Phase 3
Completed NCT02091284 - Bilateral Prefrontal Modulation in Alcoholism N/A
Completed NCT02091167 - Bilateral Prefrontal Modulation in Crack-cocaine Addiction Phase 2